Gerasimos Filippatos - Selected Publications#

Assessed end of 2022

Scopus h-index 128, Citations 122,450
Web of Science h-Index 115, Citations 86,240
Google Scholar h-index 146, Citations >150,000
Highly Cited Researcher 2015, 2016, 2017, 2018, 2019,2020, 2021, 2022
Clinical Medicine (Top 1%), Clarivate Analytics, Thomson Reuters

Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, Green JB, Rosenstock J, Schnaidt S, Brueckmann M, Pocock SJ, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators.
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Circulation. 2022 Aug 30;146(9):676-686.

Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators.
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Circulation. 2022 Feb 8;145(6):437-447.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med. 2021 Oct 14;385(16):1451-1461.

Pitt B,* Filippatos G,* Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
N Engl J Med. 2021 Dec 9;385(24):2252-2263. * equal contribution

Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD; FIDELIO-DKD Investigators.
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
J Am Coll Cardiol. 2021 Jul 13;78(2):142-152.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med. 2020 Dec 3;383(23):2219-2229.

Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators.
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Circulation. 2021 Feb 9;143(6):540-552.

Filippatos G, Angermann CE, Cleland JGF, Lam CSP, Dahlström U, Dickstein K, Ertl G, Hassanein M, Hart KW, Lindsell CJ, Perrone SV, Guerin T, Ghadanfar M, Schweizer A, Obergfell A, Collins SP.
Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure.
JAMA Cardiol. 2020 Apr 1;5(4):401-410.

Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiade M.
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section.
Eur Heart J. 2012 Sep;33(18):2265-71.

Filippatos G, Leche C, Sunga R, Tsoukas A, Anthopoulos P, Joshi I, Bifero A, Pick R, Uhal BD.
Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis.
Am J Physiol. 1999 Aug;277(2 Pt 2):H445-51.